Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Krsnaa Diagnostics Limited (KRSNAA.NS)
INR549.05
+3.65 (+0.67%)
IN NSE Healthcare Medical - Diagnostics & Research
Address
S.No.243,A-Hissa No.6/6 411019
Pune, IN
Pune, IN
CEO
Mitesh Dave
Website
krsnaadiagnostics.com
IPO
2021-08-16
ISIN INE08LI01020
Also trades on
Bombay Stock Exchange · KRSNAA.BO (INR)
National Stock Exchange of India · KRSNAA.NS (INR)
Description
Krsnaa Diagnostics Limited specializes in delivering a comprehensive range of diagnostic solutions. The company utilizes technology to provide services such as radiology, clinical pathology, and tele-radiology to diverse clients, including public and private healthcare facilities, medical colleges, and local community health centers. By December 31, 2020, its extensive network featured 1,801 diagnostic centers distributed across 13 Indian states. Established in 2010, the company maintains its headquarters in Pune, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR549.05
+3.65 (+0.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
68.2K
Beta
0.06
Float Shares
17.52M
Free Float %
54.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.88% | -2.46% | -8.67% | -14.24% | -32.35% | -23.90% | -14.67% | +8.90% | -44.38% | -44.38% | -44.38% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
549.05
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
2.26
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+7.8% Q1'26: +3.5% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+31.1% ★ Q1'26: +102.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+1.5% Q1'26: -26.8% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+15.7% ★ Q1'26: +16.8% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+13.2% ★ Q1'26: +14.5% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-0.3% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.80× ★ Q1'26: 0.75× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 4 EPS Ana. |
Mar 2027 2 Rev. Ana. 3 EPS Ana. |
Mar 2028 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
4.55B
est: 4.70B (-3.1%)
|
4.87B
est: 4.88B (-0.3%)
|
6.20B
est: 6.50B (-4.7%)
|
7.17B
est: 7.56B (-5.1%)
|
7.85B
7.64B – 8.12B
+3.9% YoY
|
10.45B
9.49B – 11.42B
+33.2% YoY
|
11.97B
11.86B – 12.09B
+14.5% YoY
|
| EBITDA |
1.46B
est: 1.95B (-25.1%)
|
1.42B
est: 2.03B (-30.2%)
|
1.61B
est: 2.70B (-40.4%)
|
2.16B
est: 3.14B (-31.3%)
|
3.26B
3.18B – 3.37B
+3.9% YoY
|
4.34B
3.94B – 4.75B
+33.2% YoY
|
4.98B
4.93B – 5.02B
+14.5% YoY
|
| EBIT |
1.05B
est: 1.45B (-27.4%)
|
878.98M
est: 1.50B (-41.5%)
|
864.95M
est: 2.00B (-56.8%)
|
1.27B
est: 2.33B (-45.3%)
|
2.42B
2.35B – 2.50B
+3.9% YoY
|
3.22B
2.92B – 3.52B
+33.2% YoY
|
3.68B
3.65B – 3.72B
+14.5% YoY
|
| Net Income |
683.88M
est: 714.66M (-4.3%)
|
621.11M
est: 637.30M (-2.5%)
|
568.37M
est: 601.15M (-5.5%)
|
776.08M
est: 976.21M (-20.5%)
|
783.50M
672.27M – 1.58B
-19.7% YoY
|
1.75B
1.29B – 2.20B
+122.9% YoY
|
2.08B
1.55B – 2.62B
+19.2% YoY
|
| SGA |
82.51M
est: 345.51M (-76.1%)
|
113.40M
est: 358.98M (-68.4%)
|
130.06M
est: 478.00M (-72.8%)
|
1.97B
est: 555.55M (+255.4%)
|
576.95M
561.83M – 596.54M
+3.9% YoY
|
768.42M
697.25M – 839.58M
+33.2% YoY
|
880.06M
871.48M – 888.64M
+14.5% YoY
|
| EPS |
22.89
est: 21.70 (+5.5%)
|
19.78
est: 19.35 (+2.2%)
|
17.90
est: 18.80 (-4.8%)
|
24.04
est: 29.72 (-19.1%)
|
30.70
20.47 – 48.20
+3.3% YoY
|
52.30
39.42 – 66.93
+70.4% YoY
|
64.10
47.11 – 79.68
+22.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
264.61M
OE per share TTM
8.07
Owner's Yield
1.49%
Maintenance CapEx ratio
350.47%
Maint CapEx / Avg PPE
100.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree India Earnings Fund EPI | 0.01% | 211.3K | 0.84% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 48.6K | 0.65% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
328.1K
Shares Outstanding
32.44M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rajendra Khivraj Mutha | Executive Chairman | 26M | male |
| Yash Prithviraj Mutha | MD & Director | 9M | male |
| Pallavi Shantilal Bhatevara | Executive Director | 4M | female |
| Mitesh Dave | Group Chief Executive Officer | — | male |
| Chandra Prakash Singh | Interim Chief Financial Officer | — | male |
| Gaurav Sachdev | National Sales Head | — | male |
| Sujoy Sudipta Bose | Company Secretary & Compliance Officer | — | male |
| Dharmendra Kumar Madan Lal Sharma | Vice President | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KRSNAA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
